IDEX Corporation (IEX)
NYSEIndustrialsSpecialty Industrial MachinerySnapshot 2026-07-09
$219.72+0.61%
Close 2026-07-09 · 1-day change
Reading IEX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IEX free→NYSEIndustrialsSpecialty Industrial MachinerySnapshot 2026-07-09
Reading IEX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IEX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
IEX represents a durable compounder with a focus on organic sales growth and earnings per share (EPS) improvement. The current thesis state is intact, but recent performance shows mixed results, indicating a cautious outlook.
The market appears to have priced in a low level of fragility, suggesting that IEX is seen as relatively cheap compared to its peers. However, there is a slight expectations gap, indicating that some growth is anticipated but not fully reflected in the valuation.
Management's focus on increasing organic sales growth and raising EPS guidance shows ambition, but recent financial results indicate limited progress. The near-term risk of missing earnings remains low, though past performance has shown volatility.
The future performance of IEX will depend on the execution of management's growth strategies and the performance of sector bellwethers like GEV, ETN, and PH. Any changes in guidance from these companies could significantly impact IEX's trajectory.
Overall, IEX's fundamentals suggest a stable position, but execution risks and sector performance are critical to watch. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates solid financial performance. There are no current threats impacting the thesis.
as of 2026-07-09
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This will indicate if demand is weakening. Orders growth is a leading indicator of future sales.
Confirms:Q2 2026 orders growth reported below 10%.
Disproves:Q2 2026 orders growth reported at 10% or higher.
Why it matters: This will show if the company can maintain its growth momentum. A decline would raise concerns about market demand.
Confirms:Q2 2026 organic sales growth was below 3%.
Disproves:Q2 2026 organic sales growth reported at 4% or higher.
Why it matters: If EPS guidance goes up, it shows management expects stronger earnings.
Confirms:Adjusted EPS guidance raised to a range of $8.35 to $8.55.
Disproves:Adjusted EPS guidance remains at or below the previous range of $8.15 to $8.35.
Why it matters: Better cash flow means the company is more efficient. It also shows stronger financial health.
Confirms:Cash flow from operations improves above 86% of net income.
Disproves:Cash flow from operations drops below 86% of net income.
Why it matters: Raising EPS guidance would signal confidence in future earnings. It shows management's optimism.
Confirms:Management raised its full-year EPS guidance. It is now higher than current estimates.
Disproves:Management keeps or lowers full-year EPS guidance.
Why it matters: Changes in leadership can affect company plans and results. Stability helps investor trust.
Confirms one read:No more leadership changes were announced after Sean Gillen became CFO.
Confirms the other:More major leadership changes were announced within six months.
Why it matters: This will indicate if the company can sustain its earnings growth. A miss could signal operational challenges.
Confirms:Adjusted diluted EPS for 2026 was below $8.35.
Disproves:Adjusted diluted EPS for 2026 reported at $8.55 or higher.
Why it matters: This segment is important for IDEX's growth. Good performance shows they are executing growth plans.
Confirms:Organic sales growth in the Health & Science Technologies segment is over 11%.
Disproves:Organic sales growth in the Health & Science Technologies segment is below 11%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.